Explore

TrendlineTrendline
Tonix Pharmaceuticals Anticipates Q3 2026 Financial Results, Analysts Project Loss Amid Revenue Growth

Tonix Pharmaceuticals Anticipates Q3 2026 Financial Results, Analysts Project Loss Amid Revenue Growth

Tonix Pharmaceuticals Anticipates Q3 2026 Financial Results, Analysts Project Loss Amid Revenue Growth
TrendlineTrendline
Vir Biotechnology Stock Surges Over 10% Following Positive Hepatitis Delta Trial Results

Vir Biotechnology Stock Surges Over 10% Following Positive Hepatitis Delta Trial Results

Vir Biotechnology Stock Surges Over 10% Following Positive Hepatitis Delta Trial Results
TrendlineTrendline
Ralph Lauren Exceeds Quarterly Expectations, Raises Full-Year Outlook Driven by Asia Growth

Ralph Lauren Exceeds Quarterly Expectations, Raises Full-Year Outlook Driven by Asia Growth

Ralph Lauren Exceeds Quarterly Expectations, Raises Full-Year Outlook Driven by Asia Growth
TrendlineTrendline
Fate Therapeutics Shares Decline 14% Amid Dilution Concerns and Q3 Results

Fate Therapeutics Shares Decline 14% Amid Dilution Concerns and Q3 Results

Fate Therapeutics Shares Decline 14% Amid Dilution Concerns and Q3 Results
TrendlineTrendline
Manulife Financial Reports 6% Q3 Core EPS Increase Driven by Asia and North American Insurance Growth

Manulife Financial Reports 6% Q3 Core EPS Increase Driven by Asia and North American Insurance Growth

Manulife Financial Reports 6% Q3 Core EPS Increase Driven by Asia and North American Insurance Growth
TrendlineTrendline
Moderna Reports Strong Q3 2026 Earnings, Raises Full-Year Guidance, and Advances Oncology Pipeline

Moderna Reports Strong Q3 2026 Earnings, Raises Full-Year Guidance, and Advances Oncology Pipeline

Moderna Reports Strong Q3 2026 Earnings, Raises Full-Year Guidance, and Advances Oncology Pipeline
TrendlineTrendline
Moderna Reports 29% Revenue Growth to $1.3 Billion in Q3 2026, Raises Full-Year Guidance

Moderna Reports 29% Revenue Growth to $1.3 Billion in Q3 2026, Raises Full-Year Guidance

Moderna Reports 29% Revenue Growth to $1.3 Billion in Q3 2026, Raises Full-Year Guidance
TrendlineTrendline
Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements
TrendlineTrendline
Niagen Bioscience Reports Q3 2026 Financial Results Amidst Increased Competition and Strategic Investments

Niagen Bioscience Reports Q3 2026 Financial Results Amidst Increased Competition and Strategic Investments

Niagen Bioscience Reports Q3 2026 Financial Results Amidst Increased Competition and Strategic Investments
TrendlineTrendline
Arcturus Therapeutics Reports Q3 2026 Financial Results and Advances mRNA Pipeline

Arcturus Therapeutics Reports Q3 2026 Financial Results and Advances mRNA Pipeline

Arcturus Therapeutics Reports Q3 2026 Financial Results and Advances mRNA Pipeline
TrendlineTrendline
Prudential Financial Reports Q3 2026 Income Decline Amidst Japan Sales Suspension

Prudential Financial Reports Q3 2026 Income Decline Amidst Japan Sales Suspension

Prudential Financial Reports Q3 2026 Income Decline Amidst Japan Sales Suspension
TrendlineTrendline
Johnson Johnson's Rybrevant Faspro Receives FDA Accelerated Approval for Head and Neck Cancer

Johnson Johnson's Rybrevant Faspro Receives FDA Accelerated Approval for Head and Neck Cancer

Johnson Johnson's Rybrevant Faspro Receives FDA Accelerated Approval for Head and Neck Cancer